Immix Biopharma, Inc. Common Stock (IMMX) Stock Price

IMMXStock
$7.98+195.56%52W
Market Cap$661.57M
P/E—
PEG Ratio—
Div yield—
Beta0.24

IMMX Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-28.89%
Price vs S&P 500 (4W)-34.68%
VGM Score60.01

IMMX Earnings Surprise History

QuarterReport dateEPS estimateEPS actualSurprise
Q2 2026-$0.18-$0.18-2.44%(-$0.00)
Q1 2026-$0.21-$0.18+13.25%(+$0.03)
Q4 2025-$0.16-$0.28-75.00%(-$0.12)
Q3 2025-$0.19-$0.24-26.32%(-$0.05)
Q2 2025-$0.16-$0.22-37.50%(-$0.06)

IMMX Analyst Recommendations

Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.10
4.17
4.15
4.15

Industry Peers — Pharmaceuticals(574)

SymbolValue ScoreGrowth ScoreMomentum ScoreP/S Ratio (TTM)Revenue Growth TTM (YoY)Gross Margin (TTM)EPS Growth (5Y)Price
IMMXImmix Biopharma, Inc. Common Stock
——B————$7.98
LLYEli Lilly & Co.DBA14.9x49.6%83.4%27.6%$1257.03
JNJJohnson & JohnsonDCB6.2x7.8%67.7%14.9%$255.56
ABBVABBVIE INC.DCA7.8x10.4%72.8%-2.9%$285.42
MRKMerck & Co., Inc.DCA5.4x4.6%77.3%21.2%$145.95
NVSNovartis AGCCB4.9x3.3%75.0%15.3%$150.62
AZNAstraZeneca PLCCBB4.3x8.6%81.3%21.9%$165.41
ABTAbbott LaboratoriesCCB3.9x8.1%56.8%8.2%$104.89
NVONovo-Nordisk A/SBCC3.5x5.6%80.7%20.7%$38.83
PFEPfizer Inc.CDA2.6x-0.2%74.7%-3.5%$29.58
VRTXVertex Pharmaceuticals IncDCB10.1x10.2%86.0%8.3%$499.74

About Immix Biopharma, Inc. Common Stock

Immix Biopharma is a clinical-stage biopharmaceutical company developing novel cell therapies for oncology and inflammatory diseases using its proprietary TME Normalization Technology. This platform enables therapeutics to penetrate tumors and simultaneously target multiple components of the tumor microenvironment. The company's pipeline includes CAR-T candidate NXC-201 for autoimmune diseases and IMX-110 for soft tissue sarcoma.